Pelthos Therapeutics Inc. (PTHS) bonds
PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.84−0.31 (-4.34%)
Close on Nov 17, 2026Market cap $26.19MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Pelthos Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Pelthos Therapeutics's 10-Q/A for the period ended Mar 31, 2026
| Issue | Coupon | Amount issued | Carrying value |
|---|---|---|---|
| Convertible Notes Convertible at $30 a share | 8.50% | $18.00M | $39.12M |
| February 2025 Bridge Note | – | $325.00K | $0 |
| July Convertible Note Convertible at $15 a share | 6.00% | $750.00K | – |
| June 2025 Bridge Note | – | $163.00K | $0 |
| May 2025 Bridge Note | – | $325.00K | – |
| May Promissory Note | – | – | $0 |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q/A.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Available | Drawn |
|---|---|---|---|
| Final Payment | – | – | $1.50M |
| Ligand Facility | $18.00M | – | – |
| Venture Loan And Security Agreement, Term Loans | $50.00M | $20.00M | $30.00M |
| Venture Loan and Security Agreement, gross | – | – | $31.50M |
See a number that looks wrong?